Pfizer and Medivation have reported the initiation of Contact and Constellation, two Phase 3 trials of the investigational drug dimebon (latrepirdine) in patients with moderate-to-severe Alzheimer’s disease (AD).
GlaxoSmithKline (GSK) and Pfizer have launched ViiV Healthcare, a new specialist HIV company. The newly launched firm aims to tackle the increasingly diverse and complex needs of people
A pivotal efficacy trial of GlaxoSmithKline Biologicals’ (GSK), RTS,S is underway in seven African countries: Burkina Faso, Gabon, Ghana, Kenya, Malawi, Mozambique and Tanzania. The trial is expected
Valeant Pharmaceuticals (Valeant) has provided additional results from the week-72 analysis of its phase IIb dose-finding clinical trial for taribavirin, a prodrug of ribavirin which is in development
The patented TruTip approach uses a nucleic acid binding matrix that is easily inserted into most standard pipette tips, including those used by electronic pipettes and liquid handling
Sigma-Aldrich has entered into a worldwide licensing agreement with Polyplus-transfection to manufacture and commercialize Zip Nucleic Acid (ZNA)oligonucleotides, a new technology that provides solutions for increased affinity for
Dow Chemical Company has moved Geoffery Merszei, executive vice president and chief financial officer, to a new role as president of Dow Europe, Middle East and Africa. He
Teva Pharmaceutical (Teva) reported a profit of $649m for the third quarter of 2009, compared with $631m in third quarter of 2008. The company reported net sales of
MeadWestvaco (MWV) has appointed Alejandro Cedeno as vice president of global innovation. In this new role, Mr Cedeno will be located at MWV’s Center for Packaging Innovation (CPI)
Texas State University and Orizon Research Institute have entered into an agreement that will permit university researchers to continue efforts through in-vivo testing to further determine the potential
Advertise With UsAdvertise on our extensive network of industry websites and newsletters.
Get the PBR newsletterSign up to our free email to get all the latest PBR
news.